Related Experiment Video
Updated: Mar 13, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Notable deals in the pharmaceutical industry in the second quarter of 2016
1Thomson Reuters, London, UK. paul.dsouza@thomsonreuters.com.
Abstract:
During the second quarter of 2016, Cortellis Competitive Intelligence had 1,014 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This was on par with the last quarter (1,011) and a substantial increase on the same quarter for the previous 1 year (659). This article will focus on highlighting a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers. An update on milestone, options and terminated deals of significance will also be presented, along with an early outlook on the next quarter's pharmaceutical licensing activity.
More Related Videos
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
FDA Approved Drugs: Changes to Approved Drugs
Pharmaceutical Equivalents
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Drug Regulation

